We compared lipids, lipid peroxidation product malondialdehyde (MDA), the acute phase reactant high-sensitivity C-reactive protein (hsCRP), interleukin 1β (IL-1β), and platelet selectin (P-selectin) between healthy controls, type 2 diabetes mellitus (DM) participants without myocardial infarction (MI), as well as type 2 DM participants with MI. Malondialdehyde, IL-1β, and P-selectin levels were significantly higher in the diabetic participants with MI than in either healthy controls or diabetic participants without MI. In the diabetic groups, fasting blood glucose (FBG) level, glycated hemoglobin (HbA1c), MDA, hsCRP, and P-selectin were all significantly positively correlated with each other. This study suggests that increased levels of oxidative stress markers, proinflammatory markers, and adhesion molecules contribute to the atherosclerotic process that eventually leads to coronary artery disease in diabetic patients.
El-Mesallamy H., Suwailem S., Hamdy N.Evaluation of C-reactive protein, endothelin-1, adhesion molecule(s), and lipids as inflammatory markers in type 2 diabetes mellitus patients. Mediators Inflamm. 2007 ;2007:73635-73642.
2.
Vinik A., Flemmer M.Diabetes and macrovascular disease. J Diabetes Complications.2002;16(3):235-245.
3.
Nishikawa T. , Edelstein D., Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787-790.
4.
Beckman JAEndothelial dysfunction. In: Marso PS , Stern MD, eds. Diabetes and Cardiovascular Disease. Integrating Science and Clinical Medicine . Philadelphia, PA: Lippincott Williams & Wilkins;2004:239-250.
5.
Eckel RH, Wassef M., Chait A., et al. Prevention conference VI: Diabetes and cardiovascular disease writing group II: Pathogenesis of atherosclerosis in diabetes. Circulation. 2002;105(18):e138-e143.
6.
Tousilous D. , Davies G., Stefanadis C., Toutouzas P., Ambrose AJInflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart. 2003;89(9):993-997.
7.
Marquardt L. , Ruf A., Mansmann U., et al. Course of platelet activation markers after ischemic stroke. Stroke. 2002;33(11):2570-2574.
8.
Shebuski RJ, Kilgore KSRole of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther. 2002; 300(3):729-735.
9.
Abraham EC, Huff TA, Cope ND, Wilson JB Jr, Bransome ED Jr, Huisman THDetermination of the glycosylated hemoglobins (HbA1) with a new microcolumn procedure. Suitability of the technique for assessing the clinical management of diabetes mellitus. Diabetes. 1978;27:931-937.
10.
Trinder P.Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol.1969;22(2):158-161.
11.
Richmond W.Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem.1973;19(12):1350-1356.
12.
Siedel J., Hagele EO, Ziegenhorn J., Wahlefeld AWReagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29(6):1075-1080.
13.
Burstein M. , Scholnick HR, Morfin R.Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11(6): 583-595.
14.
Friedewald WT, Levy RI, Fredrickson DSEstimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge . Clin Chem. 1972;18(6):499-502.
15.
Cleeman JIExecutive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486-2497.
16.
Janero DRMalondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radical Biol Med. 1990;9(6):515-540.
17.
Wright E. Jr , Scism-Bacon JL, Glass LCOxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract. 2006;60(3):308-314.
Sampson M., Davies I., Gavrilovic J., et al. Plasma matrix metalloproteinases, low density lipoprotein oxidisability and soluble adhesion molecules after a glucose load in type 2 diabetes. Cardiovasc Diabetol. 2004;3:1-7.
20.
Kalogeropoulou K., Mortzos G., Migdalis I., et al. Carotid atherosclerosis in type 2 diabetes mellitus: potential role of endothelin-1, lipoperoxides, and prostacyclin . Angiology. 2002;53(3):279-285.
21.
Fresco C., Maggioni AP, Signorini S., et al. Variations in lipoprotein levels after myocardial infarction and unstable angina: the Latin trial. Ital Heart J. 2002; 3(10):587-592.
22.
Peerapatdit T., Patchanans N., Likidlilid A., Poldee S., Sriratanasathavorn C.Plasma lipid peroxidation and antioxidant nutrients in type 2 diabetic patients. J Med Assoc Thai. 2006;89(suppl 5):S147-S155.
23.
Freeman DJ, Norrie J., Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study . Diabetes. 2002;51(5):1596-1600.
24.
Pereira FO, Frode TS, Medeiros YSEvaluation of tumour necrosis factor alpha, interleukin 2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus. Mediators Inflamm. 2006;2006(1):39062-39068.
25.
Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation. 2004; 109(21):2566-2571.
26.
Venugopal SK , Devaraj S., Yuhanna I., Shaul P., Jialal I.Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002;106(12):1439-1441.
27.
Véricel E., Januel C., Carreras M., Moulin P., Lagarde M.Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status . Diabetes. 2004;53(4):1046-1051.
28.
Ercan E., Bozdemir H., Tengiz I., et al. Decreased soluble cell adhesion molecules after tirofiban infusion in patients with unstable angina pectoris. Thromb J. 2004; 2(1):4-10.
29.
Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103(4):491-495.
30.
Woollard KJ , Kling D., Kulkarni S., Dart AM, Jackson S., Chin-Dusting J.Raised plasma soluble P-selectin in peripheral arterial occlusive disease enhances leukocyte adhesion. Circ Res. 2006;98(1):149-156.
31.
Brun E., Zoppini G., Zamboni C., Bonora E., Muggeo M.Glucose instability is associated with a high level of circulating P-selectin . Diabetes Care. 2002;24(9):1685.
32.
Daví G., Romano M., Mezzetti A., et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation. 1998;97(10):953-957.
33.
Falk E.Pathogenesis of atherosclerosis. J Am Coll Car-diol.2006;47(8 suppl):C7-C12.
